Back to Search Start Over

Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia

Authors :
Gunnarsson, Rebeqa
Mansouri, Larry
Isaksson, Anders
Göransson, Hanna
Cahill, Nicola
Jansson, Mattias
Rasmussen, Markus
Lundin, Jeanette
Norin, Stefan
Buhl, Anne Mette
Smedby, Karin Ekstrom
Hjalgrim, Henrik
Karlsson, Karin
Jurlander, Jesper
Geisler, Christian
Juliusson, Gunnar
Rosenquist Brandell, Richard
Gunnarsson, Rebeqa
Mansouri, Larry
Isaksson, Anders
Göransson, Hanna
Cahill, Nicola
Jansson, Mattias
Rasmussen, Markus
Lundin, Jeanette
Norin, Stefan
Buhl, Anne Mette
Smedby, Karin Ekstrom
Hjalgrim, Henrik
Karlsson, Karin
Jurlander, Jesper
Geisler, Christian
Juliusson, Gunnar
Rosenquist Brandell, Richard
Publication Year :
2011

Abstract

Background High-resolution genomic microarrays enable simultaneous detection of copy-number aberrations such as the known recurrent aberrations in chronic lymphocytic leukemia [del(11q), del(13q), del(17p) and trisomy 12], and copy-number neutral loss of heterozygosity. Moreover, comparison of genomic profiles from sequential patients' samples allows detection of clonal evolution. Design and Methods We screened samples from 369 patients with newly diagnosed chronic lymphocytic leukemia from a population-based cohort using 250K single nucleotide polymorphism-arrays. Clonal evolution was evaluated in 59 follow-up samples obtained after 5-9 years. Results At diagnosis, copy-number aberrations were identified in 90% of patients; 70% carried known recurrent alterations, including del(13q) (55%), trisomy 12 (10.5%), del(11q) (10%), and del(17p) (4%). Additional recurrent aberrations were detected on chromosomes 2 (1.9%), 4 (1.4%), 8 (1.6%) and 14 (1.6%). Thirteen patients (3.5%) displayed recurrent copy-number neutral loss of heterozygosity on 13q, of whom 11 had concurrent homozygous del(13q). Genomic complexity and large 13q deletions correlated with inferior outcome, while the former was linked to poor-prognostic aberrations. In the follow-up study, clonal evolution developed in 8/24 (33%) patients with unmutated IGHV, and in 4/25 (16%) IGHV-mutated and treated patients. In contrast, untreated patients with mutated IGHV (n=10) did not acquire additional aberrations. The most common secondary event, del(13q), was detected in 6/12 (50%) of all patients with acquired alterations. Interestingly, aberrations on, for example, chromosome 6q, 8p, 9p and 10q developed exclusively in patients with unmutated IGHV. Conclusions Whole-genome screening revealed a high frequency of genomic aberrations in newly diagnosed chronic lymphocytic leukemia. Clonal evolution was associated with other markers of aggressive disease and commonly included the known recurrent aberrations.

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1235077150
Document Type :
Electronic Resource
Full Text :
https://doi.org/10.3324.haematol.2010.039768